REVITALISE: A Large Observational Study Assessing the Safety and Effectiveness of Vardenafil in Men With Erectile Dysfunction and Metabolic Syndrome

Ridwan Shabsigh, Andreas Mattern, REVITALISE Study Group, Ridwan Shabsigh, Andreas Mattern, REVITALISE Study Group

Abstract

Introduction: Erectile dysfunction (ED) is prevalent in men with metabolic syndrome (MetS); therefore, it is important to characterize ED treatments in this population.

Aims: To investigate the safety and effectiveness of vardenafil in men with ED and MetS in a clinical setting.

Methods: REVITALISE is an international, prospective, single-arm, observational study in men with ED and MetS newly prescribed vardenafil. Vardenafil was prescribed at the discretion of the treating physician in line with the marketing authorization. Treatment effectiveness (International Index of Erectile Function [IIEF]) and health-related quality of life (Aging Males' Symptoms Scale) were assessed at treatment initiation, at an optional dose adjustment visit after approximately 4 weeks, and at the end of the observation period (approximately 12 weeks).

Main outcome measures: The primary outcome was an intraindividual improvement in erectile function (EF), defined as an increase of at least four points in the EF domain of the IIEF. Secondary outcomes included assessing normal EF (IIEF-EF score ≥ 26), mild ED (IIEF-EF score = 22-25), and health-related quality of life. Treatment-emergent adverse events were monitored.

Results: In the intent-to-treat population (n = 1,832, mean age = 54.0 years, mean body mass index = 31.82 kg/m(2), Asian 36.8%, white 49.9%, 20.4% with severe ED, 75.6% with mild or moderate ED, 4.0% without ED), 82.4% reported an increase of at least four points in IIEF-EF score. Median IIEF-EF score increased from 15.0 (baseline) to 25.0 at 12 weeks (P < .0001). After treatment, 45.4% and 29.4% (intent-to-treat population) had normal EF and mild ED, respectively. Improvements in the sexual, psychological, and somatic subscales of the Aging Males' Symptoms Scale were found (P < .0001). Treatment-emergent adverse events were reported by 7.19% of patients; there were no serious adverse events related to vardenafil.

Conclusion: In a clinical setting, men with ED and MetS treated with vardenafil reported improvements in EF and health-related quality of life; and the safety profile of vardenafil was acceptable. REVITALISE demonstrates that vardenafil represents a good treatment option for men with ED and MetS.

Keywords: Erectile Dysfunction; Metabolic Syndrome; Phosphodiesterase Type 5 Inhibitor; Vardenafil.

Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Figures

Figure 1
Figure 1
Study populations. aMultiple responses were possible. ITT = intent-to-treat; PDE5 = phosphodiesterase type 5; PP = per-protocol.
Figure 2
Figure 2
Analysis of IIEF domain scores. Panel A shows median IIEF domain scores for the ITT population at the initial and final visits. Panel B shows categorized IIEF-EF domain scores for the ITT population at the initial and final visits. ∗P < .0001. Lines indicate the maximum possible score achievable for each domain. ED = erectile dysfunction; IIEF = International Index of Erectile Function; IIEF-EF = International Index of Erectile Function–erectile function domain; ITT = intent-to-treat; LOCF = last observation carried forward.
Figure 3
Figure 3
Percentage of ITT population (n = 1,832) achieving Aging Males' Symptoms total score in each category. The total score for all 17 questions was categorized according to the degree of symptom severity. ITT = intent-to-treat.

References

    1. Bal K., Öder M., Şahin A.S. Prevalence of metabolic syndrome and its association with erectile dysfunction among urologic patients: metabolic backgrounds of erectile dysfunction. Urology. 2007;69:356–360.
    1. Esposito K., Giugliano F., Martedě E. High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care. 2005;28:1201–1203.
    1. Kupelian V., Shabsigh R., Araujo A.B. Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging Study. J Urol. 2006;176:222–226.
    1. Penson D.F., Latini D.M., Lubeck D.P. Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients?: Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (EXCEED) database. Diabetes Care. 2003;26:1093–1099.
    1. Walczak M.K., Lokhandwala N., Hodge M.B. Prevalence of cardiovascular risk factors in erectile dysfunction. J Gend Specif Med. 2002;5:19–24.
    1. Corona G., Mannucci E., Petrone L. A comparison of NCEP-ATPIII and IDF metabolic syndrome definitions with relation to metabolic syndrome-associated sexual dysfunction. J Sex Med. 2007;4:789–796.
    1. Kaya E., Sikka S.C., Gur S. A comprehensive review of metabolic syndrome affecting erectile dysfunction. J Sex Med. 2015;12:856–875.
    1. Park K., Hwang E.C., Kim S.-O. Prevalence and medical management of erectile dysfunction in Asia. Asian J Androl. 2011;13:543–549.
    1. Hatzimouratidis K, Eardley I, Giuliano F, et al. Guidelines on male sexual dysfunction: Erectile dysfunction and premature ejaculation. European Association of Urology. Available at: . Published 2015. Accessed January 2016.
    1. Montague DK, Jarow JP, Broderick GA, et al. The management of erectile dysfunction: an update. American Urological Association. Available at: . Published 2007. Accessed January 2016.
    1. Stief C., Porst H., Sáenz De Tejada I. Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. Int J Clin Pract. 2004;58:230–239.
    1. Hellstrom W.J.G., Gittelman M., Karlin G. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl. 2002;23:763–771.
    1. Valiquette L., Young J.M., Moncada I. Sustained efficacy and safety of vardenafil for treatment of erectile dysfunction: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc. 2005;80:1291–1297.
    1. Donatucci C., Taylor T., Thibonnier M. Vardenafil improves patient satisfaction with erection hardness, orgasmic function, and overall sexual experience, while improving quality of life in men with erectile dysfunction. J Sex Med. 2004;1:185–192.
    1. Chen K.-K., Paick J.-S., Ishii N., on behalf of the Vardenafil Study Group The efficacy and safety of vardenafil in East Asian men with erectile dysfunction. J Sex Med. 2011;4:753–761.
    1. Hatzichristou D., Montorsi F., Buvat J. The efficacy and safety of flexible-dose vardenafil (Levitra®) in a broad population of European men. Eur Urol. 2004;45:634–641.
    1. Porst H., Young J.M., Schmidt A.C. Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups. Urology. 2003;62:519–523.
    1. Van Ahlen H., Zumbé J., Stauch K. The real-life safety and efficacy of vardenafil (REALISE) study: results in men from Europe and overseas with erectile dysfunction and cardiovascular or metabolic conditions. J Sex Med. 2010;7:3161–3169.
    1. Miner M., Gilderman L., Bailen J. Vardenafil in men with stable statin therapy and dyslipidemia. J Sex Med. 2008;5:1455–1467.
    1. Goldstein I., Young J.M., Fischer J. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care. 2003;26:777–783.
    1. Eardley I., Lee J.C., Shabsigh R. Vardenafil improves erectile function in men with erectile dysfunction and associated underlying conditions, irrespective of the use of concomitant medications. J Sex Med. 2010;7:244–255.
    1. Shabsigh R., Duval S., Shah M. Efficacy of vardenafil for the treatment of erectile dysfunction in men with hypertension: a meta-analysis of clinical trial data. Curr Med Res Opin. 2007;23:2453–2460.
    1. Van Ahlen H., Wahle K., Kupper W. Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med. 2005;2:856–864.
    1. Schneider T., Gleißner J., Merfort F. Efficacy and safety of vardenafil for the treatment of erectile dysfunction in men with metabolic syndrome: results of a randomized, placebo-controlled trial. J Sex Med. 2011;8:2904–2911.
    1. BayerHealthCare. Levitra 5 mg, 10 mg, 20 mg film-coated tablets. Product information. Available at: . Published 2014. Accessed January 2016.
    1. Rosen R.C., Riley A., Wagner G. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822–830.
    1. Rosen R.C., Cappelleri J.C., Gendrano N. The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res. 2002;14:226–244.
    1. Quek K.F., Low W.Y., Razack A.H. Reliability and validity of the Malay version of the International Index of Erectile Function (IIEF-15) in the Malaysian population. Int J Impot Res. 2002;14:310–315.
    1. Heinemann L., Saad F., Zimmermann T. The Aging Males' Symptoms (AMS) scale: update and compilation of international versions. Health Qual Life Outcomes. 2003;1:15.
    1. Center for Epidemiology and Health Research (ZEG). AMS Aging Males Symptoms scale. Available at: . Published 2008. Accessed January 2016.
    1. Herdman M., Fox-Rushby J., Badia X. A model of equivalence in the cultural adaptation of HRQoL instruments: The universalist approach. Qual Life Res. 1998;7:323–335.
    1. Alberti K.G.M.M., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med. 1998;15:539–553.
    1. Comment on the provisional report from the WHO consultation. Diabet Med. 1999;16:442–443.
    1. Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA. 2001;285:2486–2497.
    1. Alberti K.G.M.M., Zimmet P., Shaw J. Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med. 2006;23:469–480.
    1. Yuan J.Q., Mao C., Yang Z.Y. A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction. Asian J Androl. 2016;18:60–65.
    1. Tan H.M., Chin C.M., Chua C.B. Efficacy and tolerability of vardenafil in Asian men with erectile dysfunction. Asian J Androl. 2008;10:495–502.
    1. Corona G., Lee D.M., Forti G., EMAS Study Group Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS) J Sex Med. 2010;7:1362–1380.
    1. Albersen M., Orabi H., Lue T.F. Evaluation and treatment of erectile dysfunction in the aging male: a mini-review. Gerontology. 2012;58:3–14.
    1. Shabsigh R., Kaufman J.M., Steidle C. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol. 2004;172:658–663.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera